BC Innovations | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BC Week In Review | Jun 9, 2014
Clinical News

TT-034: Phase I/IIa started

Benitec began an open-label, U.S. Phase I/IIa trial to evaluate single ascending-doses of IV TT-034 in up to 5 cohorts in 14 patients with chronic HCV genotype 1 infection. Benitec gained TT-034 through its October...
BC Innovations | Oct 24, 2013
Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression 1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas...
BC Week In Review | Nov 5, 2012
Company News

Benitec, Tacere deal

Benitec completed its acquisition of RNAi company Tacere for about $102.3 million newly issued ordinary shares valued at about $1.5 million (see BioCentury, Oct. 22). Benitec Biopharma Ltd. (ASX:BLT), Balmain, Australia   Tacere Therapeutics Inc....
BC Week In Review | Oct 22, 2012
Company News

Benitec, Tacere deal

Benitec will acquire RNAi company Tacere for about 102.3 million newly issued ordinary shares, which the companies valued at about $1.5 million. The shares represent a 9.5% stake in Benitec. In 2006, Tacere received an...
BC Week In Review | Feb 14, 2011
Company News

Tacere, Oncolys BioPharma deal

Tacere reacquired development and commercialization rights in Asia to its family of HCV compounds, including TT-033 and TT-034 , after it and Oncolys mutually terminated a 2007 deal. Further terms were not disclosed (see BioCentury, Oct....
BC Week In Review | Feb 8, 2010
Company News

Tacere, Pfizer deal

Pfizer exercised its option under a 2008 deal to license exclusive, worldwide rights, excluding Asia, to develop and commercialize a family of HCV compounds from Tacere. The compounds include TT-034 and TT-033, adeno-associated virus (AAV)...
BC Extra | Feb 6, 2010
Top Story

Pfizer exercises HCV option

Pfizer Inc. (NYSE:PFE) exercised an option to license exclusive, worldwide rights, excluding Asia, to develop and commercialize a family of HCV compounds from Tacere Therapeutics Inc. (San Jose, Calif.). The compounds include TT-034 and TT-033...
BioCentury | Jun 30, 2008
Strategy

Biotherapeutic shopping spree

Biotherapeutic shopping spree Company/Institution Year Deal type Products/technologies obtained California Institute for Quantitative Biosciences (QB3) 2008 Research alliance Deal to enable any researcher from UC San Francisco, UC Santa Cruz and/or UC Berkeley to collaborate...
BC Week In Review | Mar 17, 2008
Company News

Oncolys BioPharma, Tacere deal

Oncolys exercised its option to license Asian rights to develop and commercialize Tacere’s OBP-701 (TT-033) to treat HCV. The adeno-associated virus (AAV) vector containing three RNAi elements is expected to enter Phase I testing in...
Items per page:
1 - 10 of 15
BC Innovations | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BC Week In Review | Jun 9, 2014
Clinical News

TT-034: Phase I/IIa started

Benitec began an open-label, U.S. Phase I/IIa trial to evaluate single ascending-doses of IV TT-034 in up to 5 cohorts in 14 patients with chronic HCV genotype 1 infection. Benitec gained TT-034 through its October...
BC Innovations | Oct 24, 2013
Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression 1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas...
BC Week In Review | Nov 5, 2012
Company News

Benitec, Tacere deal

Benitec completed its acquisition of RNAi company Tacere for about $102.3 million newly issued ordinary shares valued at about $1.5 million (see BioCentury, Oct. 22). Benitec Biopharma Ltd. (ASX:BLT), Balmain, Australia   Tacere Therapeutics Inc....
BC Week In Review | Oct 22, 2012
Company News

Benitec, Tacere deal

Benitec will acquire RNAi company Tacere for about 102.3 million newly issued ordinary shares, which the companies valued at about $1.5 million. The shares represent a 9.5% stake in Benitec. In 2006, Tacere received an...
BC Week In Review | Feb 14, 2011
Company News

Tacere, Oncolys BioPharma deal

Tacere reacquired development and commercialization rights in Asia to its family of HCV compounds, including TT-033 and TT-034 , after it and Oncolys mutually terminated a 2007 deal. Further terms were not disclosed (see BioCentury, Oct....
BC Week In Review | Feb 8, 2010
Company News

Tacere, Pfizer deal

Pfizer exercised its option under a 2008 deal to license exclusive, worldwide rights, excluding Asia, to develop and commercialize a family of HCV compounds from Tacere. The compounds include TT-034 and TT-033, adeno-associated virus (AAV)...
BC Extra | Feb 6, 2010
Top Story

Pfizer exercises HCV option

Pfizer Inc. (NYSE:PFE) exercised an option to license exclusive, worldwide rights, excluding Asia, to develop and commercialize a family of HCV compounds from Tacere Therapeutics Inc. (San Jose, Calif.). The compounds include TT-034 and TT-033...
BioCentury | Jun 30, 2008
Strategy

Biotherapeutic shopping spree

Biotherapeutic shopping spree Company/Institution Year Deal type Products/technologies obtained California Institute for Quantitative Biosciences (QB3) 2008 Research alliance Deal to enable any researcher from UC San Francisco, UC Santa Cruz and/or UC Berkeley to collaborate...
BC Week In Review | Mar 17, 2008
Company News

Oncolys BioPharma, Tacere deal

Oncolys exercised its option to license Asian rights to develop and commercialize Tacere’s OBP-701 (TT-033) to treat HCV. The adeno-associated virus (AAV) vector containing three RNAi elements is expected to enter Phase I testing in...
Items per page:
1 - 10 of 15